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was significantly greater in patients preoperatively treated 
with 5000 rad. In our global experience, no technical or 
clinical problems occurred in patients subjected to a 
preoperative dose of 30 Gy. After these last two failures, 
whenever reduction of the tumor size is needed to facili- 
tate the procedure, we recommend that a preoperative 
radiation dose of no greater than 30 Gy be used. 
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Topical use of aprotinin in cardiac surgery 
To the Editor: 
We read with great interest he letters concerning the 
topical effect of aprotinin by Edmunds 1 and by Tabuchi, 
de Haan, and van Oeveren. a 
We 3 demonstrated the efficacy of topical aprotinin (1 
million KIU) in the pericardial cavity in reducing postop- 
erative blood loss in patients undergoing cardiac opera- 
tions. 30 'Regan and associates 4 recently reported that 
topical application of aprotinin in the pericardial cavity 
significantly reduced the postoperative blood loss after 
cardiac operations. The mechanism by which aprotinin 
exerts its effect topically differs from its systemic effect, 
wherein the mechanism of action is conservation ofplate- 
let function and inhibition of fibrinolysis. 
de Haan and associates 5 reported an increased activity 
of tissue-plasminogen activator from the pericardium and 
proposed a fibrinolysis-related bleeding tendency after 
cardiopulmonary b pass. Of equal interest is a recent 
report by Tabuchi and associates, 6 who demonstrated 
enormous activation of fibrinolysis on the surgical wound 
during cardiopulmonary b pass. Tabuchi, de Haan, and 
van Oeveren 2 have recently reported a tremendous in- 
crease of fibrin degradation products in the blood of the 
surgical wound compared with systemic blood. Low-dose 
systemic aprotinin reduced fibrin degradation products in 
wound blood by half compared with that in a control 
group (17,900 -+ 6,800 ng/ml versus 38,200 ___ 9,300 ng/ml). 
The results of these studies, 2'5' 6 combined with the 
results of Tatar, 3 and O'Regan, 4 and their colleagues, 
suggest that a local fibrinolytic state persists after closure 
of the thoracic avity and contributes to the postoperative 
blood loss. Topical aprotinin seems to exert an antifibrino- 
lyric action by which it stabilizes fibrin sealing of the 
surgical wound. 
Systemic absorption and effect of the topically applied 
aprotinin is a concern. The plasma aprotinin levels were 
measured in eight patients in our original study, and 
aprotinin could not be detected in any. However, this was 
a small number from which to reach a conclusion. There- 
fore we measured systemic drug concentrations in 30 of 
150 patients in whom we used aprotinin topically (1 
million KIU) in the pericardial cavity immediately after 
our original study at the GATA Department of Cardio- 
vascular Surgery. Systemic aprotinin levels were deter- 
mined by means of the sandwich-enzyme-linked immu- 
nosorbent assay technique at the first hour after the chest 
tubes were unclamped. Aprotinin could not be detected in 
any patient's blood. The exposure time to topical aproti- 
nin was 11.4 minutes on average. Although aprotinin is a 
small molecule (about 7000 daltons), short exposure time 
and low topical dose limit systemic absorption. Our data 
once again confirm that the drug remains restricted to the 
pericardial space and the effect is completely due to 
topical action. 
Although aprotinin has been reported as safe in earlier 
studies, a number of adverse reactions including renal 
impairment, graft occlusion, anaphylaxis after reuse, and 
disseminated intravascular coagulation after profound 
hypothermic bypass have begun to accumulate with in- 
creasing systemic use of aprotinin. The topical use of 
aprotinin will completely abolish most of the complica- 
tions and eliminate the need for prophylactic use. We 
have used topical aprotinin extensively since 1991 with no 
adverse actions or intolerance. Another important consid- 
eration is treatment cost, which may be reduced by 
approximately 80% with the topical use of the drug. 
We agree that "nothing is ever simple in the enzymatic 
stew of coagulation ''1 but believe that a simple approach 
to the problems ometimes brings better solutions. In our 
opinion, topical use of aprotinin will be established as a 
therapeutic option to reduce postoperative blood loss. It 
can at least be combined with systemic use to reduce the 
high intravenous doses. We also emphasize that careful 
surgical hemostasis i the key in reducing postoperative 
blood loss and that pharmacologic agents hould be used 
not as an alternative but a supplement to surgical hemo- 
stasis. 
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